A new study by Laboratory Corp. of America Holdings (Labcorp) has found that nearly 9 in 10 COVID-19 patients continue to have antibodies to SARS-CoV-2 proteins 10 months after infection. Published in The Lancet-affiliated Eclinicalmedicine, the study provides real-world evidence of the persistence of SARS-CoV-2 antibodies in infected individuals, though the authors said more research is needed to determine if, and to what degree, protection against reinfection persists.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanced Biological Laboratories, Amg International, Choicespine, Guard Medical, Ihealthscreen, Jenavalve, Quidel, Unity HA, Uroviu.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adventhealth, Alpha Imaging, Anpac Bio-Medical Science, Burstiq, Confluent Medical Technologies, Drawbridge Health, F-Star Therapeutics, GT Medical Technologies, Henry Schein, Inivata, Isoplexis, Jarvis Analytics, Ka Imaging, Lifebit Biotech, Mount Sinai Genomics, Nexstim, Novocure, Paige, Promis Neurosciences, Quest Diagnostics, Rulestar, Thorne Healthtech, Waters.
PARIS – Biosynex SA signed a binding offer to acquire 100% of the stock in Avalun SAS, a company developing the Labpad in vitro diagnostic device that provides rapid biological test results from small sample volumes. In Europe, Avalun is currently marketing a follow-up test for patients on anticoagulation therapy using antivitamin K agents, and a test for automated antigen detection for COVID-19.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acupath Laboratories, Advanced Human Imaging, Carestream Health, Caris Life Sciences, Essenlix, Haliodx, Hewlett Packard Enterprise, Labcorp, Max Pharma, Micron Medical, Recuro Health, Roche, Supdoc, Test Today USA, Xphyto.
As infections and deaths continue to surge in some countries so does the demand for unfettered access to the technologies behind COVID-19 vaccines and other medical products. In seeking that access, several countries are stressing the need to develop their own manufacturing capacity as they look beyond the current pandemic.
Roughly a year and a half after the start of the COVID-19 pandemic, many unknowns remain about the future of the virus. How it will mutate, how long protection from either illness or vaccination will last, when it will cease to be a pandemic and instead be endemic, even whether the worst is still ahead. And there is also an increasing acknowledgment that there remain unknowns about SARS-CoV-2’s past.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avisa Diagnostics, Binx Health, Bio-Teche, Discovery Life Sciences, Fogchain, Medline Industries, Seegene, Sherlock Biosciences, Targos Molecular Pathology, Teleflex, Water Street Healthcare Partners.
LONDON – Delaying the second dose of Pfizer Inc./Biontech SE’s COVID-19 vaccine significantly increases the antibody response in people ages 80 to 99, compared to the approved schedule of two doses three weeks apart, according to the latest data from the U.K. coronavirus immunology consortium.
